Loading...
Market
Number of countries adopting Hillchol (BBV131) for national immunization programs by the end of 2025?
2
Resolution / Starting Odds
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31+ countries • 25%
Official announcements from national health departments and international health organizations
Story
Bharat Biotech Launches Hillchol (BBV131) Oral Cholera Vaccine After Successful Trials
Aug 27, 2024, 10:39 AM
Indian vaccine manufacturer Bharat Biotech has announced the launch of its novel oral cholera vaccine, Hillchol (BBV131), following successful phase 3 trials. The vaccine, developed under license from Hilleman Laboratories, aims to address the rising global cholera cases and deaths, which have been increasing since 2021. Between early 2023 and March 2024, 824,479 cases and 5,900 deaths were reported across 31 countries. The introduction of this low-cost vaccine is considered a significant milestone in global public health efforts to combat cholera.
View original story
Similar markets
1-5 • 25%
6-10 • 25%
11-15 • 25%
More than 15 • 25%
Yes • 50%
No • 50%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
More than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 20 countries • 25%
20 to 40 countries • 25%
41 to 60 countries • 25%
More than 60 countries • 25%
More than 20 countries • 33%
10 to 20 countries • 34%
Less than 10 countries • 33%
Less than 50 countries • 25%
50 to 80 countries • 25%
81 to 120 countries • 25%
More than 120 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
India • 25%
Bangladesh • 25%
Nigeria • 25%
Other • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%